Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
FBO DAILY ISSUE OF AUGUST 16, 2006 FBO #1724
SOLICITATION NOTICE

66 -- Plethysmograph

Notice Date
8/14/2006
 
Notice Type
Solicitation Notice
 
NAICS
334516 — Analytical Laboratory Instrument Manufacturing
 
Contracting Office
Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services, 5630 Fishers Lane, Room 2129, Rockville, MD, 20857-0001
 
ZIP Code
20857-0001
 
Solicitation Number
Reference-Number-RQN-1021558
 
Response Due
8/21/2006
 
Archive Date
8/21/2006
 
Small Business Set-Aside
Total Small Business
 
Description
The Food and Drug Administration (FDA) intends to award a Purchase Order on a sole source basis for a Plethysmograph to Buxco Research Systems, Wilmington, North Carolina. Buxco Research Systems holds a U.S. patent on the whole body plethysmograph and is the sole source of this system. The vendor is the exclusive supplier of both the instrumentation and software required to operate the instrument. The whole body flow plethysmograph is a system that allows various components of airway function to be measured in small animals, including respiratory rates, airway compliance and airway resistance. This system will therefore allow us to measure changes in airway function following exposure to respiratory pathogens or allergens. We have demonstrated that respiratory rates measured using this system provides an excellent way to measure disease severity induced or exacerbated by respiratory viruses, including influenza. This system is unique is that it allows measurements to be made in live animals without anesthesia, so that we are able to follow pathogenesis and resolution of disease, using the same individual animals over the course of infection. Measurement of respiratory rate in the small animal model are easily made using the whole body plethysmograph and is an essential parameter to include to further our understanding of vaccine and drug efficacy. NO REQUEST FOR QUOTE (RFQ) IS AVAILABLE. Notwithstanding, any firm that believes it is capable of providing the required service as stated herein may submit a capability statement to document its ability to provide the required services, which will be considered if received by the seventh (7th) calendar day following the appearance of this announcement. A determination to compete this procurement based on a response to this notice is solely within the discretion of the Government. All responses or questions regarding this posting must be in writing and can be sent via email to Fred.Ettehadieh@fda.hhs.gov. No phone calls will be accepted. An award will be made in seven (7) calendar days from the date of this notice. This sole source procurement will be awarded as a simplified acquisition for commercial items in accordance with FAR Subpart 13.5.
 
Record
SN01114105-W 20060816/060814220259 (fbodaily.com)
 
Source
FedBizOpps Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  Jenny in Wanderland!  © 1994-2024, Loren Data Corp.